A Phase II Study of Patients with Recurrent Glioblastoma Treated with Maximal Safe Neurosurgical Resection, Intra- Operative Radiation Therapy (IORT) Using the Xoft® Axxent® Electronic Brachytherapy System (GLIOX) and post-radiation adjuvant Bevacizumab.
The purpose of this trial is to assess the overall survival of patients treated with the Xoft Axxent eBx System and post-radiation adjuvant Bevacizumab for single-fraction IORT following maximal neurosurgical resection of recurrent glioblastoma. A historical comparison will be made to the results of the EBRT + Bevacizumab arm of RTOG 1205.
Inclusions/Exclusions: GBM or variants (gliosarcoma, giant cell glioblastoma etc.). Subjects will be also eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made. Unequivocal radiographic evidence for tumor progression. KPS >/=60%. No > 3 relapses.